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Abstract
Endothelin-converting enzyme-1 (ECE-1) is the enzyme predominantly responsible for producing active endothelin-1 (ET-1),
a mitogenic peptide implicated in the aetiology of a number of diseases, including cancer. Elevated levels of ECE-1 have
been observed in a range of malignancies, with high expression conferring poor prognosis and aiding the acquisition of
androgen independence in prostate cancer. The mechanisms regulating the expression of ECE-1 in cancer cells are poorly
understood, hampering the development of novel therapies targeting the endothelin axis. Here we provide evidence that
the expression of ECE-1 is markedly inhibited by its 39UTR, and that alternative polyadenylation (APA) results in the
production of ECE-1 transcripts with truncated 39UTRs which promote elevated protein expression. Abolition of the ECE-1
APA sites reduced protein expression from a reporter vector in prostate cancer cells, suggesting these sites are functional.
This is the first study to identify ECE-1 as a target for APA, a regulatory mechanism aberrantly activated in cancer cells, and
provides novel information about the mechanisms leading to ECE-1 overexpression in malignant cells.
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Introduction
ET-1 is a potent mitogen for a variety of cell types, including
vascular smooth muscle cells, fibroblasts and endothelial cells, and
is able to coordinate the proliferative effects of other peptide
growth factors [1]. ET-1 binds to one of two G-protein coupled
receptors, ETAR and ETBR, leading to activation of downstream
signalling cascades promoting proliferation and chemotaxis [2].
Furthermore, ET-1 appears to stimulate pro-angiogenic factors,
such as vascular endothelial growth factor (VEGF) [3]. The
endothelin system has been implicated in the pathobiology of
numerous human cancers including those of the prostate, lung,
breast, colon and cervix, and plays a role in the aetiology of other
pathologies such as hepatic fibrosis and atherosclerosis [4].
ET-1 is generated via processing of inactive big-ET-1 by
endothelin-converting enzyme-1 (ECE-1). ECE-1 exists as four
isoforms, ECE-1a to ECE-1d, which are generated from a single
gene by the use of alternative promoters. The isoforms differ only
in their N-terminal regions; the majority of exons and the 39UTR
are common to all four isoforms [5]. The isoforms exhibit similar
catalytic activities but differ in their subcellular localisations [6].
ECE-1 is abundantly and widely expressed [7], implying an
important physiological role. ECE-1 is upregulated in a number of
cancers, including prostate cancer, leading to increased levels of
ET-1 peptide [8,9]. The mechanisms underlying the observed
upregulation, however, remain to be elucidated.
Previous studies have provided evidence that ECE-1 may be
subject to post-transcriptional regulation in hepatic stellate cells
and vascular endothelial cells [10,11]. Post-transcriptional regula-
tion, including the processing, export, localisation, turnover and
translation of messenger RNAs (mRNAs), is increasingly recog-
nised as a major means of altering gene expression levels [12].
Many of these mechanisms of post-transcriptional regulation are
directed by sequences or motifs present in the 39 untranslated
region (39UTR) of transcripts, which may be targeted by
regulatory molecules including proteins and microRNA. Micro-
RNAs (miRNAs) are small, non-coding RNA molecules which
regulate expression of target genes by binding to complementary
sequences in the 39 UTR and causing transcript degradation or
inhibiting translation [13,14]. Widespread dysregulation of
miRNA expression has been identified in numerous diseases,
including prostate cancer [15]. Furthermore, widespread trunca-
tion of 39UTR has recently been reported as a feature of cancer
cells, suggesting aberrant post-transcriptional regulation of gene
expression may be a critical contributing factor to malignant
transformation and/or disease progression.
In this study we present analysis of the post-transcriptional
regulation of ECE-1 and its implications in prostate cancer. We
provide evidence that the ECE-1 39UTR is able to regulate the
expression of ECE-1 and identify the presence of truncated
transcripts generated from alternative polyadenylation in cancer
cells.
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Experimental Procedures
Materials
RWPE-1 prostate epithelial cells were purchased from ATCC
via LGC Standards. PC-3 cells were kindly provided by Prof.
Norman Maitland (University of York, UK; [16]). CHO cells were
originally obtained from ECACC.
The pMIR-REPORT Luciferase vector and pre-miR molecules
were purchased from Ambion (Warrington, UK). The pRL-TK
vector, pSV-b-galactosidase vector and dual-luciferase reporter
assay system were from Promega (Southampton, UK). The
pcDNA3 mammalian expression vector, Lipofectamine2000,
Oligofectamine and keratinocyte serum-free medium (SFM) were
from Invitrogen (Paisley, UK).
The following antibodies were used at the following dilutions:
monoclonal anti-V5 antibody 1:500 (Invitrogen), goat polyclonal
anti-ECE-1 1:1000 (R&D Systems), rabbit polyclonal anti-Upf1
1:200 (Santa Cruz) and monoclonal anti-b-actin 1:10,000 (Sigma).
Cell Culture
PC-3 cells were routinely cultured in Hams F-12 containing 7%
(v/v) FBS and 2 mM L-glutamine. RWPE-1 cells were cultured in
Keratinocyte-SFM containing L-glutamine supplemented with
bovine pituitary extract (0.05 mg/ml) and epidermal growth factor
(5 ng/ml) (Invitrogen). CHO cells were cultured in Hams F-12
containing 10% (v/v) FBS and 2 mM L-glutamine. Huh7 cells
were cultured in DMEM containing 10% (v/v) FBS, non essential
amino acids and 2 mM L-glutamine.
Cloning of 39UTR and Site-directed Mutagenesis
The full-length ECE-1 39UTR (2710 nucleotides corresponding
to bases 2534–5243 of NCBI accession NM_001113347) was
amplified from human genomic DNA (BD Biosciences) using
Phusion polymerase (NEB) and ligated into pMIR-REPORT
Luciferase vector between the SpeI and HindIII sites. The insert
was fully sequenced.
Figure 1. The full-length ECE-1 39UTR significantly reduces luciferase activity. The full-length ECE-1 39UTR was cloned into pMIR-REPORT
luciferase vector (ECE UTR) and transfected into the cell lines indicated. Activities of Firefly and Renilla luciferase (endogenous control) were assayed
48 h post transfection. Data represent the ratio of Firefly/Renilla luciferase activities normalised to empty miReport vector (miReport) 6 S.E.M. (n = 9,
* = P,0.001 by Student t-test).
doi:10.1371/journal.pone.0083260.g001
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6 alternative polyadenylation (APA) sites were identified in the
ECE-1 39UTR. These were sequentially mutated by PCR. To
remove the SV40polyA sequence from the miReport vector, a
MluI site was introduced at either side of the SV40 sequence, the
construct digested and subsequently re-ligated.
Figure 2. The 39-UTR of ECE-1 represses ECE-1 protein expression. PC-3, RWPE-1, Huh7 and CHO cells were transiently transfected with
empty vector (1), V5-tagged ECE-1c cDNA (2) or V5-tagged ECE-1c cDNA with full-length 39 UTR (3) and immunoblotted for V5 (A). b-actin was used as
a loading control. The PC-3 blot was reprobed for ECE-1 expression. Data represent the ratio of V5:actin expression 6 S.E.M. (B; n = 3, * = P,0.05,
** = P,0.01, *** = P,0.001 by Student t-test). Real-time PCR analysis of transcript abundance in transfected PC-3 cells shown in A. V5 expression was
normalised to neomycin expression (transfection control) and U6 expression (endogenous control). n = 3, * = P,0.005 by Student t-test (C).
doi:10.1371/journal.pone.0083260.g002
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39 RACE
Total RNA was isolated from PC-3 cells using the RNeasy kit
(QIAgen). 1 mg total RNA was used to generate cDNA using
Superscript II reverse transcriptase (Invitrogen) according to
manufacturer’s instructions using TAP as a primer (GACTC-
GAGCAAGCTTCGATTTTTTTTTTTTTTTTT). 2 ml of the
cDNA reaction was used as a template for first round PCR using
an ECE-1-specific forward primer (GCTTTGCA-
CAGGTCTGGTGCTC) and AP as reverse primer (GACTC-
GAGCAAGCTTCG). Nested PCR was then performed using a
nested ECE-1-specific forward primer (AATTCCAAG-
GAGTTCTCAG) and MAP as reverse primer (AAGCTTC-
GATTTTTTTTTT). The PCR products were then A-tailed and
ligated into pCR4-TOPO (Invitrogen) according to manufactur-
er’s instructions. Constructs were sequenced using M13 forward
and reverse primers.
The ECE-1 UTR-specific sequence was then cloned into
pMIR-REPORT Luciferase between the SpeI and MluI sites. To
control for length, the reverse complement (RC) of the remaining
Table 1. The ECE-1 39UTR contains 6 putative APA sites.
Sequence Position in 39UTR Score
TTTAAA 352 bp 0.671
AATACA 366 bp 0.732
TTTAAA 397 bp 0.771
ACTAAA 1182 bp 0.113
AAGAAA 1357 bp 0.157
AATGAA 2538 bp 0.814
AATAAA 2686 bp 0.157
In silico interrogation (http://dnafsminer.bic.nus.edu.sg/) of the ECE-1 39UTR
sequence revealed the presence of six potential proximal polyadenylation
signals.
doi:10.1371/journal.pone.0083260.t001
Figure 3. The effect of the ECE-1 39UTR on luciferase activity is due to length not specific sequence. Schematic representation of the
truncated UTRs identified by 39RACE which were then cloned downstream of the Firefly luciferase gene in pMIR-REPORT (A). Empty pMIR-REPORT,
full-length ECE UTR, the six truncated UTRs and the equivalent six truncated UTRs controlled for length (RC) were transfected into PC-3 cells. Activities
of Firefly and Renilla luciferase (endogenous control) were assayed 48 h post transfection. Data represents the ratio of Firefly/Renilla activities
normalised to empty pMIR-REPORT vector (miReport) 6 S.E.M. (n = 9) (B).
doi:10.1371/journal.pone.0083260.g003
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UTR sequence was then cloned in between the MluI and HindIII
sites.
Construction of Expression Vectors
ECE-1c cDNA with an N-terminal V5 tag was ligated into the
pcDNA3 expression vector between KpnI and XbaI sites. To
make cDNA plus UTR, the full-length or truncated UTR was
ligated in immediately downstream of the cDNA.
Huh7 and CHO cells were transfected with 5 mg DNA using
Lipofectamine transfection reagent. PC-3 cells were transfected
with 15 mg DNA using TransIT-Prostate Transfection Kit (Mirus).
RWPE-1 cells were transfected with 5.4 mg DNA using TransIT-
LT1 transfection reagent (Mirus).
Luciferase Reporter Assays
Cells were co-transfected using Lipofectamine2000 with 500 ng
empty luciferase reporter vector (miReport) or 500 ng 39UTR-
luciferase reporter vector and 100 ng pRL-TK Renilla luciferase
control vector. 48 h after transfection, cells were rinsed in PBS,
lysed in passive lysis buffer and analysed using the dual-luciferase
reporter assay system according to manufacturer’s instructions.
Huh7 cells were co-transfected using Lipofectamine2000 with
500 ng 39UTR-luciferase reporter vector, 300 ng pSV-b-galacto-
sidase control vector and pre-miRNA or negative control miRNA
#1 (final concentration 47.62 nM). 48 h after transfection, cells
were rinsed in PBS, lysed in reporter lysis buffer and analysed
using the dual-luciferase reporter assay system and the b-
galactosidase enzyme assay system according to manufacturer’s
instructions.
Protein Extraction and Immunoblotting
Cells were lysed in triple detergent buffer containing protease
inhibitors and benzonase nuclease. Proteins were separated on 3–
8% tris-acetate gradient gels (Invitrogen), transferred to nitrocel-
lulose membrane, blocked and incubated with primary antibodies
overnight. After washing, membranes were incubated with HRP-
conjugated secondary antibodies for 1 hour. Densitometrical
analysis was performed using Aida v2.1 software.
Quantitative Real-time PCR
Total RNA was isolated from PC-3 cells 48 h after transfection
with V5 cDNA only or V5 cDNA plus full-length UTR using the
RNeasy mini kit (Qiagen) and treated with DNase I (Invitrogen).
cDNA was produced from 500 ng total RNA using SuperScript II
reverse transcriptase (Invitrogen) with oligo(dT) primers (Promega)
according to manufacturer’s instructions. 10 ng cDNA was then
used as template per reaction. Quantitative real-time PCR was
performed using 26 SensiMix SYBR & Fluoroscein kit (Bioline)
and 0.5 mM each primer.
V5 forward CTA ACC CTC TCC TCG GTC TCG AT (in the
V5 tag).
V5-ECE-1 reverse CCG GGG GCT GTG GAA GTT CAC
(ECE-1 specific).
The amplified product of this primer pair results only from the
reverse-transcribed V5-tagged ECE-1 construct. For each RNA
sample, triplicates were analysed with each primer set. Relative
ECE-1 RNA expression was normalised to neomycin for
transfection efficiency, and endogenous U6.
Neomycin forward CTT GCT CCT GCC GAG AAA GT.
Neomycin reverse TTC GCT TGG TGG TCG AAT G.
U6 forward CTC GCT TCG GCA GCA CA.
Figure 4. The effect of the ECE-1 39UTR on ECE protein expression depends on UTR length. PC-3 (A) or RWPE-1 (B) cells were transfected
with V5-tagged ECE-1c cDNA only or with the truncated or full-length UTR cloned immediately downstream for 48 h. Total lysates (30 mg protein)
were immunoblotted for V5; b-actin was used as a loading control. Data represent the ratio of V5:actin expression 6 S.E.M. n = 3, * = P,0.05 by
Student t-test.
doi:10.1371/journal.pone.0083260.g004
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U6 reverse AAC GCT TCA CGA ATT TGC GT.
Results
The Full-length 39UTR of ECE-1 Significantly Reduces
Luciferase Activity
In order to establish whether ECE-1 expression is subject to
post-transcriptional regulation via its 39UTR in cancer cells, the
entire 39UTR (2710 bp) was cloned into a luciferase reporter
vector. A variety of cell lines were subsequently transfected with
the ECE-1 UTR-luciferase construct or the empty luciferase
vector (Figure 1). In all cell lines tested, the full-length 39UTR
caused a significant reduction in luciferase activity compared to
empty vector as measured by luciferase reporter assay. The
greatest effect was seen in PC-3 prostate cancer cells (86%
reduction in luciferase activity) but transfection of RWPE-1, CHO
and Huh7 cells also showed a significant reduction, suggesting this
is not a cancer- or cell-line specific phenomenon.
The ECE-1 39UTR Reduces ECE-1 Protein Expression
We next examined the effect of the ECE-1 39UTR on ECE-1
protein expression. ECE-1c cDNA with an N-terminal V5 tag was
cloned into the pcDNA3 mammalian expression vector with or
without the full-length 39UTR. Use of the V5 tag allowed
detection only of heterologously expressed ECE-1; the majority of
cell lines endogenously express ECE-1. ECE-1c cDNA was used
because it is the most widely expressed isoform, and is generally
expressed at the highest level of all the isoforms [6]. A variety of
cell lines were transfected with V5-cDNA (without UTR) or V5-
UTR (with UTR) and immunoblotted for V5 (Figure 2A). In all
cases, the full-length UTR significantly reduced ECE-1 protein
expression. Again, the greatest decrease was seen in PC-3 cells
(Figure 2B).
Real-time PCR was then used to examine V5-tagged transcript
level (using primers which do not detect endogenous ECE-1
expression) in the transfected PC-3 cells, and showed that
transcript level is significantly downregulated by the full-length
UTR (Figure 2C).
The ECE-1 39UTR Contains Alternative Polyadenylation
Sites
It has recently been reported that cancer cell lines often express
high levels of transcripts with truncated 39 UTRs, which usually
result from alternative cleavage and polyadenylation [15].
Cleavage and polyadenylation is required for maturation of most
mRNA transcripts. Approximately 54% of human genes contain
alternative polyadenylation sites [17]; AAUAAA is the canonical
polyadenylation signal, but variants are also used. These variants,
including AAGAAA, AAUACA, AAUGAA and UUUAAA, are
generally used as proximal polyadenylation signals rather than the
polyadenylation signal for the longest isoform [17]. Bioinformatic
analysis revealed the 39 UTR of ECE-1 contains 6 such APA sites
of varying predicted strength (Table 1).
Figure 5. The effect of the UTR on ECE protein expression is
due to length not specific sequence. PC-3 cells were transfected
with V5-tagged cDNA, V5 cDNA plus 184 bp UTR, V5 cDNA plus
184 bp+RC, or V5 cDNA plus full-length UTR for 48 h. Total lysates
(30 mg) were immunoblotted for V5; b-actin was used as a loading
control (A). Data represent the ratio of V5:actin expression normalised
to cDNA 6 S.E.M. n = 3, *** = P,0.001 by Student t-test, n.s = not
significant (B).
doi:10.1371/journal.pone.0083260.g005
Figure 6. Removal of the APA sites reduces luciferase activity.
The SV40poly(A) tail sequence was deleted from the wild-type ECE-UTR
miReport construct (ECE SV40). The six APA sites were then all abolished
by site-directed mutagenesis (APA SV40). Constructs were transfected
into PC-3 cells for 48 h. Data represent the ratio of Firefly/Renilla
luciferase activities normalised to ECE SV406 S.E.M. (n = 9, * = P,0.05 by
Student t-test).
doi:10.1371/journal.pone.0083260.g006
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Cancer Cells Express ECE-1 mRNA Transcripts with
Truncated 39 UTRs
To investigate if the predicted APA sites are functional and
produce truncated UTRs, 39RACE (rapid amplification of cDNA
ends) was performed on RNA isolated from PC-3 cancer cells. Six
truncated transcripts, as well as the full-length UTR, were isolated
(represented in Figure 3A). These truncations matched closely, but
not completely, to the putative APA sites identified by bioinfor-
matics analysis.
The truncated UTRs identified by 39RACE were cloned into a
luciferase reporter vector and transfected into PC-3 cells to assess
the effect of these physiologically relevant truncations on protein
translation. To control for non-specific functions of UTR length
the reverse complement (RC) of the UTR segment present in the
full-length but not truncated UTR was cloned immediately
downstream of the truncated UTR, so that all RC constructs
contained 2710 nucleotides.
The resulting constructs were then transfected into PC-3 cells
and analysed by luciferase reporter assay (Figure 3B). The effect of
the UTR on luciferase activity appears to be solely due to length,
since the same specific sequence is present in both the truncated
construct and the RC construct. The UTR of 184 bp significantly
increased luciferase activity by 14.7%, but UTRs of 387 bp or
longer decreased luciferase activity.
39UTR Length Affects ECE-1 Protein Expression
Having established that 39UTR length strongly influences
translatability in a luciferase reporter system, we next analysed
the effect of the truncated UTRs on ECE-1 protein expression.
Each truncated 39UTR identified from 39RACE analysis was
cloned immediately downstream of the V5-tagged cDNA, and the
resulting constructs transfected into PC-3 or RWPE-1 cells
(Figure 4A and B). As observed using the reporter assay, an
increase in UTR length up to 184 bp increased ECE-1 expression,
in keeping with the findings of the luciferase reporter assay. UTRs
of 387 bp or 405 bp both increased protein expression beyond
that of cDNA only, but to a lesser extent. 39UTR lengths of
1108 bp, or longer, decreased protein expression significantly
below that of cDNA alone. Replacement of the deleted region of
the 39UTR with its reverse complement restored ECE-1 protein
expression to levels similar to that of the wild-type, suggesting this
observation is not due to specific sequence motifs within the
39UTR (Figure 5A, B).
Removal of the APA Sites Decreases Luciferase Activity
As discussed above, the ECE-1 UTR contains six APA sites in
addition to the distal polyadenylation signal. To assess the effect of
these APA sites the SV40 poly(A) signal was deleted from the
vector to prevent the strong poly(A) signal overriding the
endogenous polyadenylation signals. To assess the effect of the
APA sites, all six were then mutated. The wild-type UTR
construct and the mutated construct were then transfected into
PC-3 cells and luciferase activity analysed (Figure 6). Removal of
the APA sites caused a small but significant decrease of 13.5% in
luciferase activity.
Discussion
It has been previously reported that ECE-1 is upregulated in a
variety of cancers, but the mechanism of this upregulation has not
been elucidated. We demonstrate here, for the first time, that the
39UTR plays a significant role in regulating the expression of
ECE-1.
A number of recent reports have identified widespread
alterations in 39UTR length in proliferating and malignant cells,
generally manifested in the form of transcript truncations [17,18].
This truncation may free transcripts from regulation by factors,
protein or RNA (particularly microRNA), which interact with the
39UTR and influence protein expression, or influence their
translocation from the nucleus. In a subset of mantle cell
lymphoma, for example, a truncated Cyclin D1 transcript is
over-represented, leading to an increase in Cyclin D1 protein
expression [19]. Although the mechanisms underlying transcript
shortening in distinct physiological and pathophysiological states is
unclear, a variety of mechanisms are likely to be involved,
including genomic deletions, point mutations and the utilisation of
alternative polyadenylation (APA) signals. Polyadenylation is a key
step in the maturation of transcripts; most genes contain strong
polyadenylation signals which direct transcript cleavage and the
addition of a poly(A) tail. A number of genes, however, also
contain APA signals which, in certain contexts, may be utilised to
generate a truncated transcript. In cancer cells, for example, it is
thought that levels of 39 processing factors are frequently altered
(16) and these global changes may lead to changes in poly(A) site
selection. Cytoprotective heat shock protein 70 (Hsp70), for
example, is post-transcriptionally regulated via alternative poly-
adenylation (APA) and miRNAs. APA, induced by heat shock
stimulus, causes accumulation of transcripts with truncated
39UTRs. This shortening of the 39UTR both relieves the
translational repression observed with the long 39UTR, and
removes binding sites for suppressive miRNAs, causing increased
expression [20]. It has been shown by systematic analysis of
human and mouse transcriptomes that short 39UTR isoforms are
relatively more abundant when genes are highly expressed and
that poly(A) site choice is coupled to transcriptional activity [21].
Here we show that truncations in the ECE-1 39UTR lead to
increased ECE-1 mRNA and protein expression. In the course of
this study it was reported that nitric oxide (NO) causes a decrease
in ECE-1 expression, via destabilization of the transcript via the
39UTR. NO acts through a cGMP-dependent mechanism and a
region of the 39UTR containing regulatory elements involved in
this mechanism was identified [10]. A study of hepatic wound
healing detected upregulation of ECE protein expression and
identified two 39UTR-binding proteins which cause stabilization
of the transcript [11]. Although in these studies the rat ECE-1
39UTR was used, which differs substantially in both length and
sequence to the human 39UTR, this does suggest a conserved role
for the 39UTR in regulating the expression of ECE-1.
Here we provide evidence that the ECE-1 39UTR contains
APA sites, and that these may be used to generate truncated
transcripts in prostate cancer cells. Heterologous expression of
constructs containing truncations corresponding to those identified
in PC cells led to enhanced protein expression, and mutation of
the APA sequences led to a decrease in expression in a reporter
assay, most likely due to an increase in expression of the full length
39UTR resulting from the removal of APA-mediated transcript
cleavage.
The mechanisms underlying the observed increase in ECE-1
expression on truncation of its 39UTR remain to be determined.
The data presented here suggest that this phenomenon is purely a
function of transcript length rather than the result of elimination of
specific sequences; replacement of the deleted regions with the
reverse complement restored the repression of gene expression.
This is at odds with the recent reports in rats, in which specific
regulatory regions in the 39UTR were identified [10,11], and
suggests that different mechanisms may exist in different cell types
and/or species. Work is ongoing to identify the precise molecular
Post-Transcriptional Regulation of ECE-1
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mechanisms underlying the 39UTR-induced suppression of ECE-1
expression, but our findings suggest this may be a novel
mechanism responsible for ECE-1 over-expression in cancer cells
and may therefore represent a novel therapeutic target.
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